| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $10,008 ) |
| | 2022 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 000 | 2 | FDA | 10/20/2021 | -$207 |
| | 2022 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 9/26/2022 | $10,215 |
|
| Issue Date FY: 2021 ( Subtotal = -$483,116 ) |
| | 2021 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 000 | 2 | FDA | 12/22/2020 | $0 |
| | 2021 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 001 | 2 | FDA | 8/10/2021 | $0 |
| | 2021 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 000 | 1 | NIH | 3/19/2021 | -$61,882 |
| | 2021 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA246991 | SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | 000 | 2 | NIH | 4/23/2021 | -$391,540 |
| | 2021 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA250889 | Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE) | 000 | 1 | NIH | 5/26/2021 | $0 |
| | 2021 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44HL145964 | A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | 000 | 1 | NIH | 6/30/2021 | -$1,212 |
| | 2021 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 8/22/2021 | -$28,483 |
| | 2021 | 2018 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA221513 | A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease. | 000 | 2 | NIH | 11/9/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,267,171 ) |
| | 2020 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA250824 | First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy | 000 | 1 | NIH | 4/3/2020 | $400,000 |
| | 2020 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA250889 | Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE) | 000 | 1 | NIH | 5/19/2020 | $396,664 |
| | 2020 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA246991 | SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | 001 | 2 | NIH | 3/31/2020 | $985,075 |
| | 2020 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA246991 | SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | 002 | 2 | NIH | 9/21/2020 | $1,000,000 |
| | 2020 | 2020 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 000 | 2 | FDA | 12/31/2019 | $485,432 |
| | 2020 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44HL145964 | A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | 000 | 1 | NIH | 11/20/2019 | $0 |
| | 2020 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44HL145964 | A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | 001 | 1 | NIH | 2/21/2020 | $0 |
| | 2020 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 11/6/2019 | $0 |
| | 2020 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 11/6/2019 | $0 |
| | 2020 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA246991 | SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | 000 | 1 | NIH | 2/13/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,539,688 ) |
| | 2019 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44HL145964 | A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients | 000 | 1 | NIH | 8/29/2019 | $212,653 |
| | 2019 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 9/17/2019 | $294,590 |
| | 2019 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R41OD028767 | Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo. | 000 | 1 | NIH | 9/17/2019 | $18,124 |
| | 2019 | 2019 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA246991 | SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients | 000 | 1 | NIH | 9/17/2019 | $1,014,321 |
| | 2019 | 2018 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 000 | 1 | FDA | 7/2/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,486,828 ) |
| | 2018 | 2018 | ONCOIMMUNE INC | 1275 KINNEAR RD | COLUMBUS | OH | 43212-1155 | FRANKLIN | USA | R44CA221513 | A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease. | 000 | 2 | NIH | 8/17/2018 | $982,509 |
| | 2018 | 2018 | ONCOIMMUNE INC | 9430 KEY WEST AVE STE 113 | ROCKVILLE | MD | 20850-6345 | MONTGOMERY | USA | R44CA221513 | A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease. | 001 | 2 | NIH | 9/12/2018 | $4,319 |
| | 2018 | 2018 | ONCOIMMUNE INC | 1275 KINNEAR RD | COLUMBUS | OH | 43212-1155 | FRANKLIN | USA | R01FD006089 | Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016) | 000 | 1 | FDA | 7/30/2018 | $500,000 |
|
| Issue Date FY: 2017 ( Subtotal = $1,017,478 ) |
| | 2017 | 2017 | ONCOIMMUNE INC | 1275 KINNEAR RD | COLUMBUS | OH | 43212-1155 | FRANKLIN | USA | R44CA221513 | A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease. | 000 | 1 | NIH | 9/19/2017 | $1,017,478 |
| | 2017 | 2015 | ONCOIMMUNE INC | 1275 KINNEAR RD | COLUMBUS | OH | 43212-1155 | FRANKLIN | USA | R43AI108115 | Targeting endogenous sialidases for treatment of endotoxic shock | 000 | 2 | NIH | 1/26/2017 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $195,452 ) |
| | 2015 | 2015 | ONCOIMMUNE INC | 333 PARKLAND PLAZA | ANN ARBOR | MI | 48103 | WASHTENAW | USA | R43AI108115 | Targeting endogenous sialidases for treatment of endotoxic shock | 000 | 2 | NIH | 7/16/2015 | $195,452 |
|
| Issue Date FY: 2014 ( Subtotal = $734,040 ) |
| | 2014 | 2014 | ONCOIMMUNE INC | 333 PARKLAND PLAZA | ANN ARBOR | MI | 48103 | WASHTENAW | USA | R01NS080821 | CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study | 000 | 2 | NIH | 7/29/2014 | $534,084 |
| | 2014 | 2014 | ONCOIMMUNE INC | 333 PARKLAND PLAZA | ANN ARBOR | MI | 48103 | WASHTENAW | USA | R43AI108115 | Targeting endogenous sialidases for treatment of endotoxic shock | 000 | 1 | NIH | 7/23/2014 | $199,956 |
|
| Issue Date FY: 2013 ( Subtotal = $546,203 ) |
| | 2013 | 2013 | ONCOIMMUNE INC | 333 PARKLAND PLAZA | ANN ARBOR | MI | 48103 | WASHTENAW | USA | R01NS080821 | CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study | 000 | 1 | NIH | 8/5/2013 | $546,203 |
|
| Issue Date FY: 2011 ( Subtotal = $305,333 ) |
| | 2011 | 2011 | ONCOIMMUNE INC | 333 PARKLAND PLAZA | ANN ARBOR | MI | 48103 | WASHTENAW | USA | R43AI092874 | NOVEL THERAPEUTICS FOR SEPSIS | 000 | 1 | NIH | 8/30/2011 | $155,180 |
| | 2011 | 2011 | ONCOIMMUNE | 1275 Kinnear Rd | Columbus | OH | 43212-1155 | FRANKLIN | USA | R43AR061252 | TARGETING HOST RESPONSE TO DAMP FOR THERAPY OF RHEUMATOID ARTHRITIS | 000 | 1 | NIH | 4/18/2011 | $150,153 |
| | 2011 | 2010 | ONCOIMMUNE | 1474 BRIDGETON DRIVE | COLUMBUS | OH | 43224 | FRANKLIN | USA | R44NS041692 | CD24 AS THERAPEUTIC TARGET FOR MULTIPLE SCLEROSIS-PHASE II COMPETING RENEWAL | 000 | 6 | NIH | 4/26/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $493,610 ) |
| | 2010 | 2010 | ONCOIMMUNE | 1275 Kinnear Rd | Columbus | OH | 43212-1155 | FRANKLIN | USA | R44NS041692 | CD24 AS THERAPEUTIC TARGET FOR MULTIPLE SCLEROSIS-PHASE II COMPETING RENEWAL | 000 | 6 | NIH | 3/29/2010 | $493,610 |
|
| Issue Date FY: 2009 ( Subtotal = $1,444,734 ) (Continued on the next page) |
|
